Biomedical Engineering Reference
In-Depth Information
50. Dranitzki-Elhalel M, Huang JH, Schmidt W, Rachmilewitz J,
Tykocinski ML. (2003) CTLA-4-FasL induces alloantigen-
specific hyporesponsiveness. J. Immunol. 170, 5842-5850.
51. Dranitzki-Elhalel M, Huang JH, Rachmilewitz J, Pappo O,
Parnas M, Schmidt W, et al. (2006) CTLA-4-FasL
inhibits allogeneic responses in vivo. Cell. Immunol. 239,
129-135.
52. Orbach A, Rachmilewitz J, Parnas M, Huang JH, Tykocinski
ML, Dranitzki-Elhalel M. (2007) CTLA-4
FasL induces early
apoptosis of activated T cells by interfering with anti-
apoptotic signals. J. Immunol. 179, 7287-7294.
53. Zhang HG, Heike Y, Yang P, Wang Z, Wang X, Curiel DT,
Zhou T, Mountz JD. (1998) Induction of specific T-cell
tolerance by adenovirus-transfected, Fas ligand-producing
antigen presenting cells. Nature Biotechnol. 16,
1045-1049.
54. Chai JG, Bartok I, Scott D, Dyson J, Lechler R. (1998) T:T
antigen presentation by activated murine CD8
รพ
T cells
induces anergy and apoptosis. J. Immunol. 160, 3655-3665.
55. Jin Y, Qu A, Wang GM, Hao J, Gao X, Xie S. (2004)
Simultaneous stimulation of Fas-mediated apoptosis and
blockade of costimulation prevent autoimmune diabetes in
mice
during cerebral ischemia. J. Cereb. Blood Flow Metab. 27,
534-544.
65. Jakubowski A, Browning B, Lukashev M, Sizing I, Thomp-
son JS, Benjamin CD, et al. (2002) Dual role for TWEAK in
angiogenic regulation. J. Cell. Sci. 115, 267-274.
66. Kirk SL, Karlik SJ. (2003) VEGF and vascular changes in
chronic neuroinflammation. J. Autoimmun. 21, 353-363.
67. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D,
Khrestchatisky M, et al. (2002) TWEAK is expressed by glial
cells, induces astrocyte proliferation and increases EAE
severity. J. Neuroimmunol. 133, 116-123.
68. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang
MZ, et al. (2004) Tumor necrosis factor-like weak inducer
of apoptosis-induced neurodegeneration. J. Neurosci. 24,
8237-8244.
69. Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A,
Giegerich G. (2005) Targeting fibroblast growth factor-induc-
ible-14 signaling protects from chronic relapsing experimen-
tal autoimmune encephalomyelitis. J. Neuroimmunol. 159,
55-65.
70. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA,
Koornstra JJ, Wesseling J, et al. (2004) Tissue distribution of
the death ligand TRAIL and its receptors. J. Histochem.
Cytochem. 52, 821-831.
71. Zauli G, Secchiero P. (2006) The role of the TRAIL/TRAIL
receptors system in hematopoiesis and endothelial cell biol-
ogy. Cytokine Growth Factor Rev. 17, 245-257.
72. Song K, Chen Y, Goke R, Wilmen A, Seidel C, Goke A, et al.
(2000) Tumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL) is an inhibitor of autoimmune inflammation and
cell cycle progression. J. Exp. Med. 191, 1095-1104.
73. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y.
(2001) Roles of TNF-related apoptosis-inducing ligand in
experimental autoimmune encephalomyelitis. J. Immunol.
166, 1314-1319.
74. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y,
Nishimura Y. (2005) Prevention of experimental autoimmune
encephalomyelitis by transfer of embryonic stem cell-derived
dendritic cells expressing myelin oligodendrocyte glyco-
protein peptide along with TRAIL or programmed death-1
ligand. J. Immunol. 174, 1888-1897.
75. Cretney E, McQualter JL, Kayagaki N, Yagita H,
Bernard CC, Grewal IS, et al. (2005) TNF-related
apoptosis-inducing ligand (TRAIL)/Apo2L suppresses exper-
imental autoimmune encephalomyelitis in mice. Immunol.
Cell Biol. 83, 511-519.
76. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH.
(2003) Critical roles of tumor necrosis factor-related
apoptosis-inducing ligand in type 1 diabetes. Diabetes 52,
2274-2278.
77. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L,
Grattan M, et al. (2003) Blockade of tumor necrosis factor-
related apoptosis-inducing ligand exacerbates type 1 diabetes
in NOD mice. Diabetes 52, 1967-1975.
78. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA,
Peschon J, Chen YH. (2003) Defective thymocyte apoptosis
induced
by multiple
low-dose
streptozotocin.
Gene Ther. 11, 982-991.
56. Feng YG, Jin YZ, Zhang QY, Hao J, Wang GM, Xie SS.
(2005) CTLA4-fas ligand gene transfer mediated by adeno-
virus induces long-time survival of murine cardiac allografts.
Transplant. Proc. 37, 2379-2381.
57. Shi W, Chen M, Xie L. (2007) Prolongation of corneal
allograft survival by CTLA4-FasL in a murine model.
Graefes Arch. Clin. Exp. Ophthalmol. 245, 1691-1697.
58. Lau HT, Yu M, Fontana A, Stoeckert CJ, Jr. (1996) Prevention
of islet allograft rejection with engineered myoblasts express-
ing FasL in mice. Science 273, 109-112.
59. Winkles JA. (2008) The TWEAK-Fn14 cytokine-receptor
axis:
discovery,
biology
and
therapeutic
targeting.
Nat. Rev. Drug Discov. 7, 411-425.
60. Falschlehner C, Schaefer U, Walczak H. (2009) Following
TRAIL's path in the immune system. Immunology 127,
145-154.
61. Maecker H, Varfolomeev E, Kischkel F, Lawrence D,
LeBlanc H, Lee W, et al. (2005) TWEAK attenuates
the transition from innate to adaptive immunity. Cell 123,
931-944.
62. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters
S, Li H, et al. (2010) The TWEAK-Fn14 system is a critical
regulator of denervation-induced skeletal muscle atrophy in
mice. J. Cell Biol. 188, 833-849.
63. Polavarapu R, Gongora MC, Winkles JA, Yepes M. (2005)
Tumor necrosis factor-like weak inducer of apoptosis increases
the permeability of the neurovascular unit through nuclear
factor-kappa B pathway activation. J. Neurosci. 25, 10094-
10100.
64. Zhang X, Winkles JA, Gongora MC, Polavarapu R,
Michaelson JS, HahmK, et al. (2006) TWEAK-Fn14 pathway
inhibition protects the integrity of the neurovascular unit
Search WWH ::
Custom Search